These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 27287872

  • 1. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
    Chida S, Okayama H, Noda M, Saito K, Nakajima T, Aoto K, Hayase S, Momma T, Ohki S, Kono K, Takenoshita S.
    Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
    [Abstract] [Full Text] [Related]

  • 2. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D, Okayama H, Saito K, Ashizawa M, Thar Min AK, Endo E, Kase K, Yamada L, Kikuchi T, Hanayama H, Fujita S, Sakamoto W, Endo H, Saito M, Mimura K, Saze Z, Momma T, Ohki S, Kono K.
    Carcinogenesis; 2020 Jul 10; 41(5):591-599. PubMed ID: 31754689
    [Abstract] [Full Text] [Related]

  • 3. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival.
    Torres S, Garcia-Palmero I, Herrera M, Bartolomé RA, Peña C, Fernandez-Aceñero MJ, Padilla G, Peláez-García A, Lopez-Lucendo M, Rodriguez-Merlo R, García de Herreros A, Bonilla F, Casal JI.
    Clin Cancer Res; 2015 Nov 01; 21(21):4892-902. PubMed ID: 26206869
    [Abstract] [Full Text] [Related]

  • 4. Lumican and versican are associated with good outcome in stage II and III colon cancer.
    de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Bril H, Beliën JA, Fijneman RJ, Meijer GA.
    Ann Surg Oncol; 2013 Dec 01; 20 Suppl 3(Suppl 3):S348-59. PubMed ID: 22711178
    [Abstract] [Full Text] [Related]

  • 5. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.
    N Engl J Med; 2016 Jan 21; 374(3):211-22. PubMed ID: 26789870
    [Abstract] [Full Text] [Related]

  • 6. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann HB, Meijer S, Meijer GA.
    Ann Surg Oncol; 2012 Jul 21; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [Abstract] [Full Text] [Related]

  • 7. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S, Jiang T, Tang H, Cui F, Liu C, Guo F, Lu H, Xue Y, Jiang W, Peng Z, Yan D.
    J Gastroenterol Hepatol; 2015 Apr 21; 30(4):680-8. PubMed ID: 25238407
    [Abstract] [Full Text] [Related]

  • 8. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
    Di Narzo AF, Tejpar S, Rossi S, Yan P, Popovici V, Wirapati P, Budinska E, Xie T, Estrella H, Pavlicek A, Mao M, Martin E, Scott W, Bosman FT, Roth A, Delorenzi M.
    J Natl Cancer Inst; 2014 Oct 21; 106(10):. PubMed ID: 25246611
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 21; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients.
    Dekervel J, Hompes D, van Malenstein H, Popovic D, Sagaert X, De Moor B, Van Cutsem E, D'Hoore A, Verslype C, van Pelt J.
    Clin Cancer Res; 2014 Apr 15; 20(8):2159-68. PubMed ID: 24486594
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
    Hazelbag S, Kenter GG, Gorter A, Fleuren GJ.
    Int J Cancer; 2004 Dec 20; 112(6):1020-8. PubMed ID: 15386352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.
    Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, Lee KY, Kim NK, Chung HC.
    J Cancer Res Clin Oncol; 2016 Sep 20; 142(9):2051-9. PubMed ID: 27447697
    [Abstract] [Full Text] [Related]

  • 16. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
    Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delis-van Diemen PM, Tijssen M, van Essen HF, de Lange-de Klerk ES, Beliën JA, Stockmann HB, Meijer S, Meijer GA.
    Eur J Cancer; 2011 Aug 20; 47(12):1837-45. PubMed ID: 21621406
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival.
    Zhao Z, Han FH, Yang SB, Hua LX, Wu JH, Zhan WH.
    World J Gastroenterol; 2015 Jan 28; 21(4):1140-7. PubMed ID: 25632186
    [Abstract] [Full Text] [Related]

  • 20. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD, Lozano JJ, Cuatrecasas M, Alonso-Espinaco V, Maurel J, Mármol M, Hörndler C, Ortego J, Alonso V, Escudero P, Ramírez G, Petry C, Lasalvia L, Bohmann K, Wirtz R, Mira A, Castells A.
    Int J Cancer; 2013 Mar 01; 132(5):1090-7. PubMed ID: 22833293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.